138 related articles for article (PubMed ID: 24474395)
1. A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix.
Sasaki T; Nishi H; Nagata C; Nagai T; Nagao T; Terauchi F; Isaka K
Int J Clin Oncol; 2014 Dec; 19(6):1059-64. PubMed ID: 24474395
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia inducible factor-1 mediates upregulation of urokinase-type plasminogen activator receptor gene transcription during hypoxia in cervical cancer cells.
Nishi H; Sasaki T; Nagamitsu Y; Terauchi F; Nagai T; Nagao T; Isaka K
Oncol Rep; 2016 Feb; 35(2):992-8. PubMed ID: 26718775
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E2 receptor 3 (EP3) signaling promotes migration of cervical cancer via urokinase-type plasminogen activator receptor (uPAR).
Ye Y; Peng L; Vattai A; Deuster E; Kuhn C; Dannecker C; Mahner S; Jeschke U; von Schönfeldt V; Heidegger HH
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2189-2203. PubMed ID: 32488496
[TBL] [Abstract][Full Text] [Related]
4. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Gnessi L; Catania A; Pellizzo MR; Nardi F; Mian C; De Antoni E; D'Armiento M; Frati L
J Clin Endocrinol Metab; 2011 Feb; 96(2):504-8. PubMed ID: 21106716
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the value of uPAR of serum and tissue on patients with cervical cancer.
Jing J; Zheng S; Han C; Du L; Guo Y; Wang P
J Clin Lab Anal; 2012 Jan; 26(1):16-21. PubMed ID: 24833530
[TBL] [Abstract][Full Text] [Related]
6. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
[TBL] [Abstract][Full Text] [Related]
7. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Lee KH; Bae SH; Lee JL; Hyun MS; Kim SH; Song SK; Kim HS
Oncology; 2004; 66(3):210-7. PubMed ID: 15218312
[TBL] [Abstract][Full Text] [Related]
8. [Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma].
Wang D; Wang T
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jun; 19(12):529-31. PubMed ID: 16176001
[TBL] [Abstract][Full Text] [Related]
9. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
10. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
[TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
12. Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients.
Kotzsch M; Magdolen V; Greither T; Kappler M; Bache M; Lautenschläger C; Füssel S; Eckert AW; Luther T; Baretton G; Würl P; Taubert H
BMC Cancer; 2011 Jun; 11():273. PubMed ID: 21702998
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
Janisch F; D'Andrea D; Iwata T; Kimura S; Abufaraj M; Enikeev D; Glybochko PV; Karakiewicz PI; Nyirady P; Fajkovic H; Haitel A; Seebacher V; Rink M; Shariat SF
Urol Oncol; 2020 May; 38(5):423-432. PubMed ID: 32209281
[TBL] [Abstract][Full Text] [Related]
14. [Risk factors and prognosis of node-positive cervical carcinoma].
Feng SY; Zhang YN; Liu JG
Ai Zheng; 2005 Oct; 24(10):1261-6. PubMed ID: 16219145
[TBL] [Abstract][Full Text] [Related]
15. [Expressions and clinical significance of urokinase-type plasminogen activator (uPA) and uPA receptor (uPAR) in tongue squamous cell carcinoma].
Wang QX; Wang TX; Sun CF; Zhang J
Shanghai Kou Qiang Yi Xue; 2006 Feb; 15(1):85-7. PubMed ID: 16525618
[TBL] [Abstract][Full Text] [Related]
16. Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases.
Kita Y; Fukagawa T; Mimori K; Kosaka Y; Ishikawa K; Aikou T; Natsugoe S; Sasako M; Mori M
Br J Cancer; 2009 Jan; 100(1):153-9. PubMed ID: 19050704
[TBL] [Abstract][Full Text] [Related]
17. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
18. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of eukaryotic initiation factor 5A2 (EIF5A2) is associated with cancer progression and poor prognosis in patients with early-stage cervical cancer.
Yang SS; Gao Y; Wang DY; Xia BR; Liu YD; Qin Y; Ning XM; Li GY; Hao LX; Xiao M; Zhang YY
Histopathology; 2016 Aug; 69(2):276-87. PubMed ID: 26799253
[TBL] [Abstract][Full Text] [Related]
20. Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Kawasaki K; Hayashi Y; Wang Y; Suzuki S; Morita Y; Nakamura T; Narita K; Doe W; Itoh H; Kuroda Y
J Gastroenterol Hepatol; 1998 Sep; 13(9):936-44. PubMed ID: 9794194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
